Novacyt S.A. (AIM:NCYT) Approval of genesig COVID-19 3G PCR test in UK

Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation

Paris, France and Eastleigh, UK – 6 December 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s genesig® COVID-19 3G Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”), making it the Company’s seventh PCR test to be added to the CTDA register of approved COVID-19 diagnostic products.

The genesig ® COVID-19 3G test, CE marked in April 2021, is designed to detect three separate SARS-CoV-2 gene targets (ORF1ab, M gene, and S genes) from combined nasal and oropharyngeal sample types. As seen during the COVID-19 pandemic, the prevalence of mutations with biological significance within the spike protein of SARS-CoV-2 meant the need to test for more than one gene target at a time increased.

James McCarthy, Acting Group CEO of Novacyt, commented:

“The approval of our COVID-19 3G test, our seventh product to be approved under the UK’s CTDA legislation, reinforces the market-leading quality of our tests. We believe the ability of our COVID-19 3G test to simultaneously target three separate genes within SARS-CoV-2 provides a highly accurate option for detection. This latest approval ensures we are well-positioned with our consolidated COVID-19 portfolio for any potential future outbreaks and as we continue to focus on our wider diagnostic product offering as part of our growth strategy.”

The status of the Company’s current CTDA submissions is as follows:

For further information, please refer to www.novacyt.com or contact:

Contacts

Novacyt SA

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

+44 (0)1276 600081


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.

Tweet
WhatsApp
Email
Pocket
Share
Share